Synthesis and properties of second-generation 2-5A-antisense chimeras with enhanced resistance to exonucleases

Journal of Medicinal Chemistry

Volumn 40, Issue 18, 1997, Pages 2959-2966

  Li, Guiying ^a,c   Xiao, Wei ^a   Torrence, Paul F ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Bldg 8 ^*  (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EXONUCLEASE; PHOSPHODIESTERASE; SNAKE VENOM;

ARTICLE; CHIMERA; HALF LIFE TIME; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENINE NUCLEOTIDES; ALKALINE PHOSPHATASE; CHIMERA; DRUG STABILITY; EXONUCLEASES; HALF-LIFE; HUMANS; INDICATORS AND REAGENTS; KINETICS; OLIGONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES; PHOSPHORIC DIESTER HYDROLASES; SNAKE VENOMS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030881695     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970227d     Document Type: Article

References (42)

1. Belasco, J., Brawerman, G., Eds. Control of Messenger RNA Stability; Academic Press: New York, 1993.
2. Baserga, R., Denhart, D. T., Eds. Antisense Strategies. Ann. N.Y. Acad. Sci. 1993, 660, 1-353.
3. Crooke, S. T.; Lebleu, B. Antisense Reseach and Applications. CRC Press: Boca Raton, FL, 1993.
4. Torrence, P. F.; Maitra, R. K.; Lesiak, K.; Khamnei, S.; Zhou, A.; Silverman, R. H. Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1300-1304.
5. Lesiak, K.; Khamnei, S.; Torrence, P. F. 2′,5′-Oligoadenylate: antisense chimeras - synthesis and properties. Bioconjugate Chem. 1993, 4, 467.
6. Maran, A.; Maitra, R. K.; Kumar, A.; Dong, B.; Xiao, W.; Li, G.; Williams, B. R. G.; Torrence, P. F.; Silverman, R. H. Blockage of NF-kB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994, 265, 789-792.
7. Maitra, R. K.; Li, G.; Xiao, W.; Dong, B.; Torrence, P. F.; Silverman, R. H. Catalytic cleavage of an RNA target by 2-5A antisense and RNase L. J. Biol. Chem. 1995, 270, 15071-15075.
8. Torrence, P. F.; Xiao, W.; Li, G.; Lesiak, K.; Khamnei, S.; Maran, A.; Maitra, R.; Dong, B.; Silverman, R. H. (2′,5′)-Oligoadenylate antisense chimeras for the targeted ablation of RNA. In Carbohydrates: Synthetic Methods and Advances in Antisense Therapeutics; Cook, Sanghvi, Eds.; ACS Symposium Series; American Chemical Society: Washington, DC, 1994; pp 118-132.
9. Torrence, P. F.; Xiao, W.; Li, G.; Khamnei, S. Development of 2′,5′-oligonucleotides as potential therapeutic agents. Current Med. Chem. 1994, 1, 176-191.
10. Johnston, M. I.; Torrence, P. F. The role of interferon-induced proteins, double-stranded RNA, and 2′,5′-oligoadenylate in the interferon-mediated inhibition of viral translation. In Interferon, Mechanisms of Production and Action; Friedman, R. M., Ed.; Elsevier Science: Amsterdam, 1984; Vol. 3, pp 189-298.
11. Zhou, A.; Hassel, B. A.; Silverman, R. H. Expression cloning of 2-5A-dependent RNase - a uniquely regulated mediator of interferon action. Cell 1993, 72, 753-765.
12. Torrence, P. F.; Imai, J.; Lesiak, K.; Jamoulle, J.; Sawai, H. Oligonucleotide structural parameters that influence binding of 5′-O-triphosphoadenylyl-(2′→5′)-adenylyl- (2′→5′)-adenosine to the 5′-O-triphosphoadenylyl-(2′→5′)-adenylyl- (2′→5′)-adenosine dependent endoribonuclease: chain length, phosphorylation state and heterocyclic base. J. Med. Chem. 1984, 27, 726-733.
13. Xiao, W.; Li, G.; Lesiak, K.; Dong, B.; Silverman, R. H.; Torrence, P. F. Synthesis of a 5′-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease. Bioorg. Med. Chem. Lett. 1994, 4, 2609-2614.
14. Xiao, W.; Player, M. R.; Li, G.; Zhang, K.; Lesiak, K.; Torrence, P. F. Synthesis and characterization of composite nucleic acids containing 2′,5′-oligoriboadenylate linked to antisense DNA. Antisense Nucleic Acid Drug Dev. 1996, 6, 247-258.
15. Swiderski, P. M.; Bertrand, E. L.; Kaplan, B. E. Polystyrene reverse-phase ion-pair chromatography of chimeric ribozymes. Anal. Biochem. 1994, 216, 83-88. Janik, B. Physicochemical Characteristics of Oligonucleotides and Polynucleotides; IFI/ Plenum: New York, 1971; p 42.
16. Swiderski, P. M.; Bertrand, E. L.; Kaplan, B. E. Polystyrene reverse-phase ion-pair chromatography of chimeric ribozymes. Anal. Biochem. 1994, 216, 83-88. Janik, B. Physicochemical Characteristics of Oligonucleotides and Polynucleotides; IFI/ Plenum: New York, 1971; p 42.
17. Sanghvi, Y. S., Cook, P. D., Eds. Carbohydrate Modifications in Antisense Research; American Chemical Society: Washington, DC, 1994; pp 1-232.
18. Matteucci, M. D.; Wagner, R. W. In pursuit of antisense. Nature 1996, 384, 20-22.
19. Lamond, A. I.; Sproat, B. S. Antisense Oligonucleotides made of 2′-O-alkylRNA: their properties and applications in RNA biochemistry. FEBS Lett. 1993, 325, 123-127.
20. Kawasaki, A. M.; Casper, M. D.; Freier, S. M.; Lesnik, E. A.; Zounes, M. C.; Cummins, L. L.; Gonzalez, C.; Cook, P. D. Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 1993, 36, 831-841.
21. Vichier-Guerre, S.; Pompon, A.; Lefebvre, I.; Imbach, J. L. New insights into the resistance of α-oligonucleotides to nucleases. Antisense Res. Dev. 1994, 4, 9-18.
22. Miller, P. S.; McParland, K. B.; Jayaraman, K.; Ts'o, P. o. P. Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 1981, 20, 1874-1880.
23. Asseline, U.; Hau, J.-F.; Czernecki, S.; Le Diguarher, T.; Perlat, M.-C.; Valery, J.-M.; Thuong, N. T. Synthesis and physicochemical properties of oligonucleotides built with either α-L or β-L nucleotides units and covalently linked to an acridine derivative. Nucleic Acids Res. 1991, 19, 4067-4074.
24. Sanghvi, Y. S.; Cook, P. D. Carbohydrates: synthetic methods and applications in antisense therapeutics. In Carbohydrate Modifications in Antisense Research; Sanghvi, Y. S., Cook, P. D., Eds.; American Chemical Society: Washington, DC, 1994; pp 1-22.
25. Stein, C. A.; Cheng, Y. C. Antisense oligonucleotidesas therapeutic agents - Is the bullet really magical? Science 1993, 261, 1004-1012.
26. Giles, R. V.; Spiller, D. G.; Tidd, D. M. Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anti-Cancer Drug Des. 1993, 8, 33-51.
27. Shaw, J.-P.; Kent, K.; Bird, J.; Fishback, J.; Froehler, B. Modified deoxyoligonucleotides stable to exonuclease degeradation in serum. Nucleic Acids Res. 1991, 19, 747-750.
28. (a) Boutorine, A. S.; Venyaminova, A. G.; Repkova, M. N.; Sergueyeva, Z. A.; Pyshnyi, D. V. Effect of derivation of ribophosphate backbone and terminal ribophosphate groups in oligonucleotides on their stability and interaction with eukaryotic cells. Biochimie 1994, 76, 23-32.
29. (b) Ortigao, J. F.; Rosch, H.; Selter, H.; Frohlich, A.; Lorenz, A.; Montenarh, M.; Seliger, H. Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: a minimal modification protecting against nucleolytic degradation. Antisense Res. Dev. 1992, 2, 129-146.
30. Gamper, H. B.; Reed, M. W.; Cox, T.; Virosco, J. S.; Adams, A. D.; Gall, A. A.; Scholler, J. K.; Meyer, R. B., Jr. Facile preparation of nuclease resistant 3′ modified oligonucleotides. Nucleic Acids Res. 1993, 21, 145-150.
31. Zendegui, J. G.; Vasquez, K. M.; Tinsley, J. H.; Kessler, D. J.; Hogan, M. E. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotides. Nucleic Acids Res. 1992, 20, 307-314.
32. Hoke, G. D.; Draper, K.; Frier, S. M.; Gonzalez, C.; Driver, V. B.; Zounes, M. C.; Ecker, D. J. Effects of phosphorothiate capping on antisense oligonucleotides stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 1991, 19, 5743-5748.
33. Ghosh, M. K.; Ghosh, K.; Cohen, J. S. Phosphorothioate-phosphodiester oligonucleotides co-polymers: assessment for antisense application. Anti-Cancer Drug Des. 1993, 8, 15-32.
34. Thomas, M.; Kosciolek, B.; Wang, N.; Rowley, P. Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cells. Leukemia Res. 1994, 18, 401-408.
35. Peyman, A.; Uhlmann, E. Minimally modified oligonucleotides - Combination of end-capping and pyrimidine-protection. Biol. Chem. Hoppe-Seyler 1996, 377, 67-70.
36. Degols, G.; Leonetti, J.-P.; Benkirane, M.; Devaux, C.; Lebleu, B. Poly(l-lysine)-conjugated oligonucleotides promote sequence-specific inhibition of acute HIV-1 infection. Antisense Res. Dev. 1992, 2, 293-301.
37. Zhu, T.; Wei, Z.; Tung, C.-H.; Dickerhof, W. A.; Breslauer, K. J.; Georgopoulis, D. E.; Leibowitz, M. J.; Stein, S. Oligonucleotide-poly-L-ornithine conjugates: binding to complemetary DNA and RNA. Antisense Res. Dev. 1993, 3, 265-275.
38. Boado, R. J.; Pardridge, W. M. Complete inactivation of target mRNA by biotinylated antisense oligonucleotides-avidin conjugates. Bioconjugate Chem. 1994, 5, 406-410.
39. Tang, J. Y.; Temsamani, J.; Agrawal, S. A self-stabilized antisense oligonucleotide phosphorothioates; properties and anti-HIV activity. Nucleic Acids Res. 1993, 21, 2729-2735.
40. Poddevin, B.; Meguenni, S.; Elias, I. E.; Vasseur, M.; Blumenfeld, M. Improved anti-herpes simplex virus type I activity of a phosphodiester antisense oligonucleotide containing a 3′-terminal hairpin-like structure. Antisense Res. Dev. 1994, 4, 147-154.
41. Bruin, G. J. M.; Bornsen, K. O.; Husken, D.; Gassmann, E.; Widmer, H. M.; Paulus, A. Stability measurements of antisense oligonucleotides by capillary gel electrophoresis. J. Chromatogr. A 1995, 709, 181-195.
42. Cirino, N. M.; Li, G.; Xiao, W.; Torrence, P. F.; Silverman, R. H. Targeting RNA for decay in respiratory syncytial virus infected cells with 2′→5′ oligoadenylate-antisense. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1937-1942.